Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Nov;313(2):e233099.
doi: 10.1148/radiol.233099.

Aquaporin-4 Immunoglobulin G-seropositive Neuromyelitis Optica Spectrum Disorder MRI Characteristics: Data Analysis from the International Real-World PAMRINO Study Cohort

Affiliations
Multicenter Study

Aquaporin-4 Immunoglobulin G-seropositive Neuromyelitis Optica Spectrum Disorder MRI Characteristics: Data Analysis from the International Real-World PAMRINO Study Cohort

Claudia Chien et al. Radiology. 2024 Nov.

Abstract

Background Patients with neuromyelitis optica spectrum disorder (NMOSD) are often seropositive for antibodies against aquaporin-4 (AQP4). The importance of MRI monitoring in this disease requires evaluation. Purpose To profile MRI features from a large international cohort with AQP4 immunoglobulin G (IgG)-seropositive NMOSD (from the Parallel MRI in NMOSD [PAMRINO] study) and to evaluate and confirm existing knowledge regarding the incidence, location, and longitudinal development of characteristic lesions in the central nervous system associated with AQP4-IgG-seropositive NMOSD. Materials and Methods In this retrospective study (from August 2016 to January 2019), MRI and clinical data were collected from 17 NMOSD expert sites in 11 countries across four continents. Clinical features and lesions identified at cross-sectional and longitudinal MRI were assessed. No formal statistical tests were used to compare observations; however, means, SDs, and 95% CIs are reported when evaluating lesion frequencies. Results Available T1-weighted and T2-weighted MRI scans in patients with AQP4-IgG-seropositive NMOSD (n = 525) were read. Among the 525 patients, 320 underwent cerebral MRI examinations with T2-weighted hyperintense cerebral (264 of 320; 82.5%), cerebellar (44 of 320; 13.8%), and brainstem (158 of 321 [49.2%], including one lesion observed at cervical spinal cord [SC] MRI) lesions. Lesions in the optic nerves, analyzed from 152 MRI examinations, were mainly found in the central (81 of 92; 88%) and posterior (79 of 92; 86%) sections (bilaterally in 39 of 92; 42%). Longitudinally extensive transverse myelitis was the predominant SC lesion pattern (upper compartment from 322 MRI examinations, 133 of 210 [63.3%]; and lower compartment from 301 MRI examinations, 149 of 212 [70.3%]). However, nonlongitudinal extensive transverse myelitis lesions were also observed frequently (105 of 210; 50.0%) in the cervical SC. Clinical data (n = 349; mean age, 44 years ± 14 [SD]; 202 female patients) and acute lesions at contrast-enhanced (CE) MRI (n = 58, performed within 30 days of the last attack) were evaluated. CE lesions were detected in the cerebrum (eight of 13; 62%), optic nerves (14 of 19; 74%), or chiasm (three of four; 75%) within 15 days of any relapse. In the upper SC (29 of 44; 66%), CE lesions were frequently observed up to 20 days after a clinical myelitis event. Conclusion A high incidence of abnormal brain MRI examinations and nonlongitudinal extensive SC lesions was found in patients in PAMRINO with AQP4-IgG-seropositive NMOSD. © RSNA, 2024 Supplemental material is available for this article.

PubMed Disclaimer

Conflict of interest statement

Disclosures of conflicts of interest: C.C. Grants from Roche, Novartis, Alexion; speaker and writing honoraria from Bayer and the British Society for Immunology; Standing Committee on Science Member for the Canadian Institutes of Health Research. V.C.e.S. Grant support from F Hoffman-La Roche. E.G. Employment from the Medical Image Analysis Center Basel, Switzerland. D.M. No relevant relationships. H.Z. Research grants from Novartis; payment or honoraria for lectures from Novartis. D.B.B. Consulting fees from Alexion, Novartis, Merck, Horizon. M.I.I. No relevant relationships. A.A. Honoraria for lectures from Alexion; patents planned, issued, or pending from Koc University School of Medicine; Advisory Board member, Novartis. U.T. No relevant relationships. S.S. Speaker honoraria from Merck-Serono, Pacific Healthcare (Thailand), Menarini (Thailand), Biogen Idec, UCB (Thailand), Eisai, Sanofi-Aventisa, Terumo BCT, and Novartis; meeting support from Merck (Thailand), Eisai (Thailand), Roche (Thailand), Eli Lilly (Thailand), Meditop (Thailand). L.P. No relevant relationships. A.D. No relevant relationships. M.J.S. No relevant relationships. R.F. No relevant relationships. P.Q. No relevant relationships. C.T. No relevant relationships. I.L. No relevant relationships. V.K. No relevant relationships. M.A.H. No relevant relationships. H.S.K. Payment for lectures from Roche; payment for expert testimony from the Israel Health Ministry; support for meetings from Roche. D.L.R. Research support from MS Canada, National Multiple Sclerosis Society, Consortium of Multiple Sclerosis Centers (CMSC), and Roche Canada; consulting fees from Alexion, Biogen, EMD Serono, Novartis, Roche, and Sanofi Aventis; payment for lectures from Alexion, Biogen, Novartis, Roche, and Touch IME; support for meetings from EMD Serono; participation on a DataSafety Monitoring Board for Alexion, Amgen, Biogen, EMD Serono, Novartis, Roche, Sanofi, Aventis. L.W. No relevant relationships. D.O. No relevant relationships. K.N. No relevant relationships. H.A. Grants or contracts from Genentech, BMS, Sanofi, Novartis, UCB, Corevitas/Guthy-Jackson Charitable Foundation; royalties from UpToDate; consulting fees from Genentech, Horizon, Alpine, Cycle, Axonics; payment for lectures from Biogen, Genentech, Alexion, BMS, Horizon; support for meetings from Genentech; participation on a DataSafety Monitoring Board from Genentech, Alpine, Cycle, Axonics; assistant editor, Neurology. M.O.S. No relevant relationships. Y.M.D. Grant support from NIH NIAID Autoimmune Center of Excellence (UM1-AI110557, UM1 AI144298-01), CMSC, Chugai, PCORI, Genzyme-Sanofi, Novartis, and Genentech; consulting fees and/or grant support from Acorda, Bayer Pharmaceutical, Biogen Idec, Chugai Pharmaceutical, EMD Serono, Genzyme-Sanofi, Novartis, Questor, Genentech, and Teva Neuroscience; payment for lectures from Biogen Idec, EMD Serono, Horizon/Amgen; support for meetings and/or travel from Biogen Idec, Horizon/Amgen, Novartis, Genzyme; participation on a DataSafety Monitoring Board or Advisory Board for Genzyme, Novartis; grant review board member, NIH, FDA, NMSS; equipment receipt from Novartis, Chugai, Bristol Myers Squibb. J.H. Grants from Friedrich-Baur-Stiftung, Merck; personal fees and non-financial support from Bayer, Celgene, Merck, Alexion, Novartis, Roche, Horizon, and Biogen; nonfinancial support from the Guthy-Jackson Charitable Foundation and the Sumaira Foundation; supported by the German Federal Ministry of Education and Research; payment for lectures from Merck, Alexion, Novartis, Roche, Celgene, Biogen Bayer, Horizon, Sumaira Foundation, and Guthy-Jackson Charitable Foundation; payment for expert testimony from Merck, Alexion, Novartis, Roche, Celgene, Biogen Bayer, Horizon, Sumaira Foundation, and Guthy-Jackson Charitable Foundation. N.A. No relevant relationships. P.B.S. Employer paid for neuroradiology course in Turkey at the ESNR. I.K. Grants or contracts from Genentech/Roche, Novartis; royalties from Wolters-Kluwer, consulting fees from Genentech, Horizon, and Alexion Pharmaceuticals. M.R. Speaker honoraria from Roche, Alexion, Horizon; travel reimbursement from Roche, Alexion, Horizon; advisory boards for Roche, Alexion, Horizon. S.B. Consulting fees for Alexion, Roche; payment for lectures from Alexion, Novartis. S.A. No relevant relationships. B.M. No relevant relationships. A.M.J. No relevant relationships. M.W. No relevant relationships. S.G. No relevant relationships. L.J.C. Grant from the Guthy-Jackson Charitable Foundation, NIH, Health Resource and Services Administration, Centers for Disease Control, Utah Highway Safety Office. M.R.Y. Grant support from the Guthy-Jackson Charitable Foundation; support for meetings from the Guthy-Jackson Charitable Foundation. T.J.S. Consulting relationships with companies related to Graves’ disease and thyroid-associated opthalmopathy. A.U.B. Patents for retinal image analysis, multiple sclerosis serum biomarkers, perceptive visual computing; stock/stock options in Motognosis, Nocturne. J.W. Participation on a DataSafety Monitoring Board or Advisory Board for Hoffmann LaRoche; stock/stock options for Hoffmann LaRoche; employed by Hoffmann LaRoche. F.P. Grant support NeuroCure Clinical Research Center, German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy-Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche; consulting fees from Alexion, Roche, Horizon, Neuraxpharm; honoraria for lectures from Almirall, Bayer, Biogen, GlaxoSmithKline, Hexal, Merck, Sanofi Genzyme, Novartis, Viela Bio, UCB, Mitsubishi Tanabe, Celgene, Guthy-Jackson Charitable Foundation, Serono, Roche; support for meetings from Merck, Guthy-Jackson Charitable Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe, Celgene; participation on advisory board for Celgene, Roche, UCB, Merck; academic editor, PLos One, associate editor, Neurology Neuroimmunology & Neuroinflammation.

References

    1. Jarius S , Paul F , Weinshenker BG , Levy M , Kim HJ , Wildemann B . Neuromyelitis optica . Nat Rev Dis Primers 2020. ; 6 ( 1 ): 85 . - PubMed
    1. Lerch M , Schanda K , Lafon E , et al. . More Efficient Complement Activation by Anti-Aquaporin-4 Compared With Anti-Myelin Oligodendrocyte Glycoprotein Antibodies . Neurol Neuroimmunol Neuroinflamm 2022. ; 10 ( 1 ): e200059 . - PMC - PubMed
    1. Kim HJ , Paul F , Lana-Peixoto MA , et al. . MRI characteristics of neuromyelitis optica spectrum disorder: an international update . Neurology 2015. ; 84 ( 11 ): 1165 – 1173 . - PMC - PubMed
    1. Chien C , Scheel M , Schmitz-Hübsch T , et al. . Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity . Mult Scler 2019. ; 25 ( 14 ): 1926 – 1936 . - PubMed
    1. Ciccarelli O , Cohen JA , Reingold SC , Weinshenker BG ; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders . Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders . Lancet Neurol 2019. ; 18 ( 2 ): 185 – 197 . - PubMed

Publication types

LinkOut - more resources